medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-17-106-112medsovet-2155Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYПОДАГРИЧЕСКИЙ АРТРИТ – СОВРЕМЕННЫЙ ВЗГЛЯД НА ПРОБЛЕМУGOUTY ARTHRITIS – MODERN VIEW OF THE PROBLEMМазуровВ. И.MazurovV. I.

Академик РАН, доктор медицинских наук, профессор.

Санкт-Петербург

RAS academician, MD, Prof.

ПетроваМ. С.PetrovaM. S.

Кандидат медицинских наук.

Санкт-Петербург

PhD in medicine.

Saint-Petersburg

ИнамоваО. В.InamovaO. V.

Кандидат медицинских наук.

Санкт-Петербург

PhD in medicine.

Saint-Petersburg

МусейчукМ. М.MuseichukM. M.

Saint-Petersburg

Северо-Западный государственный медицинский университет им. И.И. МечниковаРоссияMechnikov North-Western State Medical UniversityRussian Federation201709112017017106112Copyright © Мазуров В.И., Петрова М.С., Инамова О.В., Мусейчук М.М., 20172017Мазуров В.И., Петрова М.С., Инамова О.В., Мусейчук М.М.Mazurov V.I., Petrova M.S., Inamova O.V., Museichuk M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2155

Подагра относится к достаточно частым ревматологическим  заболеваниям, значимость которых становится все более важной междисциплинарной проблемой.

Известно, что около 2,5% мужчин старше 30 лет и женщин старше 50 лет страдают подагрой. К 80-летнему возрасту заболевание регистрируется уже у 9% мужчин и 6% женщин. Рост заболеваемости, высокая коморбидность,  а также низкая комплаентность больных подагрой ставят все новые вопросы при выборе адекватной комплексной терапии.

Несмотря на то, что лечение этого заболевания хорошо известно и широко обсуждается в литературе, стойкой ремиссии подагры удается достичь очень редко. В литературе имеются данные о том, что менее ½ пациентов с подагрой получают уратснижающую терапию, при этом нередко препараты назначаются в дозах, явно недостаточных для получения эффекта [1].

Gout is a fairly common rheumatic disease, the significance of which becomes an increasingly important interdisciplinary problem. It is known that about 2.5% of men over the age of 30 and women over the age of 50 suffer from gout. By the age of 80 y.o. the disease is registered already in 9% of men and 6% women. The increased incidence, high comorbidity, and low compliance of patients with gout put new questions when the adequate complex therapy is sought.

Despite the fact that the treatment of this disease is well known and widely discussed in the literature, it’s possible to achieve remission of gout only in very rare cases. In the literature, there is evidence that less than ½ of patients with gout get ordinary therapy, while often drugs are prescribed in doses not sufficient to obtain the effect [1].

подаграгиперурикемияфебуксостаталлопуринолрекомендации EULAR по лечению подагрыgouthyperuricemiafebuxostatallopurinolEULAR recommendations for the treatment of goutReferencesRichette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 2017, 76: 29-42.Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 2017, 76: 29-42.Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout. New insights into pathogenesis and treatment. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65(3): 215-221.Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout. New insights into pathogenesis and treatment. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65(3): 215-221.Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Annals of Internal Medicine. 2005, 143: 499-516.Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Annals of Internal Medicine. 2005, 143: 499-516.Sanderson IR, He Y. Nucleotide uptake and metabolism by intestinal epithelial cells. The Journal of Nutrition, 1994 January, 124: 124S-160S.Sanderson IR, He Y. Nucleotide uptake and metabolism by intestinal epithelial cells. The Journal of Nutrition, 1994 January, 124: 124S-160S.Sonoda T, Tatibana M. Metabolic fate of pyrimidines and purines in dietary nucleic acids ingested by mice. Biochimica et Biophysica Acta (BBA), 1978, 521: 55-66.Sonoda T, Tatibana M. Metabolic fate of pyrimidines and purines in dietary nucleic acids ingested by mice. Biochimica et Biophysica Acta (BBA), 1978, 521: 55-66.Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis if hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Research and Therapy, 2006, 8(Suppl 1): S4.Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis if hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Research and Therapy, 2006, 8(Suppl 1): S4.Sorensen LB. Degradation of uric acid in man. Metabolism, 1959, 8: 687-703.Sorensen LB. Degradation of uric acid in man. Metabolism, 1959, 8: 687-703.Rudolph FB. The biochemistry and physiology of nucleotides. The Journal of Nutrition, 1994 January, 124: 124S-160S.Rudolph FB. The biochemistry and physiology of nucleotides. The Journal of Nutrition, 1994 January, 124: 124S-160S.Mikuls TR, Farrar JT, Bilker WB et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis, 2005 Feb, 64(2): 267-72.Mikuls TR, Farrar JT, Bilker WB et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis, 2005 Feb, 64(2): 267-72.Kutzing MK, Firestein BL. Altered uric acid levels and disease states. The Journal of Pharmacology and Experimental Therapeutics, 2008, 324: 1-7.Kutzing MK, Firestein BL. Altered uric acid levels and disease states. The Journal of Pharmacology and Experimental Therapeutics, 2008, 324: 1-7.So A. Developments in the scientific and clinical understanding of gout. Arthritis Research & Therapy, 2008, 10: 221.So A. Developments in the scientific and clinical understanding of gout. Arthritis Research & Therapy, 2008, 10: 221.Liu-Bryan R, Terkeltaub R. Evil humors take their toll as innate immunity makes gouty joints TREM-ble. Arthritis & Rheumatism, 2006 Feb, 54(2): 383-386.Liu-Bryan R, Terkeltaub R. Evil humors take their toll as innate immunity makes gouty joints TREM-ble. Arthritis & Rheumatism, 2006 Feb, 54(2): 383-386.Murakami Y, Akahoshi T, Hayashi I, Endo H, Kawai S, Inoue M, Kondo H, Kitasato H. Induction of Triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals. Arthritis & Rheumatism, 2006 Feb, 54(2): 455-462.Murakami Y, Akahoshi T, Hayashi I, Endo H, Kawai S, Inoue M, Kondo H, Kitasato H. Induction of Triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals. Arthritis & Rheumatism, 2006 Feb, 54(2): 455-462.Martinon F. Mechanisms of uric acid crystalmediated autoinflammation. Immunological Reviews, 2010, 233: 218-232.Martinon F. Mechanisms of uric acid crystalmediated autoinflammation. Immunological Reviews, 2010, 233: 218-232.Заболеваемость населения России (в 2000–2006 гг.). Статистические материалы Министерства здравоохранения и социального развития РФ (за 2001–2007 гг.).Заболеваемость населения России (в 2000–2006 гг.). Статистические материалы Министерства здравоохранения и социального развития РФ (за 2001–2007 гг.).Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis, 2014, 73: 1598-600. doi:10.1136/annrheumdis-2014-205304.Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis, 2014, 73: 1598-600. doi:10.1136/annrheumdis-2014-205304.Grassi W, Meenagh G, Pascual E, Filippucci E. Crystal clear-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum, 2006, 36(3): 197-202.Grassi W, Meenagh G, Pascual E, Filippucci E. Crystal clear-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum, 2006, 36(3): 197-202.Nicolaou S, Yong-Hing C, Galea-Soler S, Hou D, Louis L, Munk P. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting. Am J Roentgenol, 2010, 194: 1072-1078.Nicolaou S, Yong-Hing C, Galea-Soler S, Hou D, Louis L, Munk P. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting. Am J Roentgenol, 2010, 194: 1072-1078.Choi H, Burns L, Shojania K, Koenig N, Reid G, Abufayyah M et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis, 2012, 71: 1466-1471.Choi H, Burns L, Shojania K, Koenig N, Reid G, Abufayyah M et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis, 2012, 71: 1466-1471.Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Annals Epidemiol, 1998, 8: 250-261. doi: 10.1016/S1047-2797(97)00204-4.Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Annals Epidemiol, 1998, 8: 250-261. doi: 10.1016/S1047-2797(97)00204-4.Moi JH, Sriranganathan MK, Falzon L et al. Lifestyle interventions for the treatment of gout: a summary of 2 Cochrane systematic reviews. J Rheumatol, 2014, 92(Suppl): 26-32. doi:10.3899/jrheum.140459.Moi JH, Sriranganathan MK, Falzon L et al. Lifestyle interventions for the treatment of gout: a summary of 2 Cochrane systematic reviews. J Rheumatol, 2014, 92(Suppl): 26-32. doi:10.3899/jrheum.140459.Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol, 2011, 23: 192-202. doi:10.1097/BOR.0b013e3283438e13.Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol, 2011, 23: 192-202. doi:10.1097/BOR.0b013e3283438e13.Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol, 2011, 23: 156-160. doi:10.1097/BOR.0b013e3283432d35.Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol, 2011, 23: 156-160. doi:10.1097/BOR.0b013e3283432d35.Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology, 2007, 58: 450-457. doi:10.1177/0003319707303444.Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology, 2007, 58: 450-457. doi:10.1177/0003319707303444.Jalal DI, Chonchol M, Chen W et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis, 2013, 61: 134-146. doi:10.1053/j.ajkd.2012.07.021.Jalal DI, Chonchol M, Chen W et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis, 2013, 61: 134-146. doi:10.1053/j.ajkd.2012.07.021.Schlesinger N, Mysler E, Lin HY et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study. Ann Rheum Dis, 2011 Jul, 70(7): 1264-1271.Schlesinger N, Mysler E, Lin HY et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study. Ann Rheum Dis, 2011 Jul, 70(7): 1264-1271.Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich), 2013, 15: 435-442. doi:10.1111/j.1751-7176.2012.00701.x.Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich), 2013, 15: 435-442. doi:10.1111/j.1751-7176.2012.00701.x.Goicoechea M, Garcia de Vinuesa S, Verdalles U et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis, 2015, 65: 543-549. doi:10.1053/j.ajkd.2014.11.016.Goicoechea M, Garcia de Vinuesa S, Verdalles U et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis, 2015, 65: 543-549. doi:10.1053/j.ajkd.2014.11.016.Saag KG, Whelton A, Becker MA et al. Impact of febuxostat on renal function in gout subjects with moderate-to-severe renal impairment. Arthritis Rheumatol, 2016. [Epub ahead of print 19 Feb 2016]. doi:10.1002/art.39654doi:10.1002/art.39654.Saag KG, Whelton A, Becker MA et al. Impact of febuxostat on renal function in gout subjects with moderate-to-severe renal impairment. Arthritis Rheumatol, 2016. [Epub ahead of print 19 Feb 2016]. doi:10.1002/art.39654doi:10.1002/art.39654.

The authors declare that there are no conflicts of interest present.